|| Checking for direct PDF access through Ovid
Nonalcoholic fatty liver disease (NAFLD) is commonly associated with components of the metabolic syndrome. Disorders range from simple hepatic steatosis to nonalcoholic steatohepatitis, which has potentially severe outcomes. The aim of treatment of NAFLD is to reverse obesity-associated lipotoxicity and insulin resistance via lifestyle interventions. There is growing evidence for the use of various pharmacological agents in the treatment of this condition.